Integrated cold chain Target pharma and biotech firms expanding cell and gene therapies that require end-to-end, temperature-controlled logistics, biostorage, and cryopreservation; position Cryoport as a one-stop partner for risk mitigation and supply chain certainty.

Global expansion assets Leverage recent facility expansions in Clermont-Ferrand and Pont-du-Chateau to pursue customers needing scalable packaging, labeling, kitting, and GMP biorepository capabilities across clinical and commercial stages, including regulatory and QP services.

Strategic partnerships Highlight collaboration opportunities with biotechs and fertility tech providers (e.g., Verismo Therapeutics, TMRW Life Sciences) to integrate Cryoport’s cryopreservation and logistics with proprietary processes for faster trial enrollment and secure offsite storage.

Innovation pipeline Promote new offerings such as HE 800 C freezer and Cryoport Express HV3 shipping system to clients seeking advanced storage and air-cargo transport capabilities, emphasizing efficiency gains and global reach.

Financial health signals Use positive EBITDA momentum in Q2 2026 and reaffirmed revenue outlook to engage growth-focused prospects who value scalable, revenue-generating partnerships and long-term service contracts in high-value biologics logistics.